Founded in 2004 and headquartered in Heidelberg, Germany, Precisis uses bioelectronic methods to direct therapeutic currents at defined target areas of the brain. Their medical device, EASEE®, is a thin electrode pad that is inserted beneath the skin and positioned over the epileptic origin in the brain with anatomical precision. It has received CE-mark for the treatment of focal epilepsies in September 2022 after two clinical trials showed tremendous efficacy and safety results. Precisis' unique achievement has been to miniaturise bioelectric pacemakers for the brain, making them easily tolerable for patients. The company's team is passionate and committed to developing and marketing medical technology that reduces the burden of epilepsy and other neurological disorders.